First one–year real world evidence data with the monoclonal antibody Erenumab in Germany (1873)

Objective: This data collection aims to characterize the use of erenumab in clinical practice from the treating physician’s point of view. Background: Erenumab, the first-in-class fully human monoclonal antibody against the calcitonin-gene-related-peptide (CGRP) receptor, has demonstrated efficacy and safety/tolerability in clinical studies. Even so, randomized controlled trials have limitations and may not offer a representative patient population encountered in clinical routine. Although real-life data complements existing data of RCTs, there is limited real-world evidence available for this new class of antibodies targeting the CGRP pathway. Design/Methods: Data of 70 headache centers has been collected by an online survey from July to December 2019 across Germany. First, the use of erenumab is characterized from the treating physicians perception with regard to therapy decision, patient profiles and quality of life of the patients. Thereafter, in a retrospective collection, each center documented 10–20 individual consecutive episodic and chronic migraine patients already into 3 months of erenumab treatment were assessed for their treatment effects and satisfaction of treatment outcome. Results: An interim analysis of 109 patients showed a reduction of 8 migraine days on average under erenumab therapy. Physicians reported that 75% of their patients already a first response after their first injection. 80% of the patients felt a reduction of intensity and 92% patients had a reduction of frequency of their attacks. 80 % of the patients were rated as ‘much improved’ and ‘very much improved’ by the treating physician on the global impression score. The full data set including at least 700 erenumab patients will be available for AAN congress. Conclusions: The TELESCOPE study provides real world evidence data for erenumab in Germany regarding daily treatment routines, typical patient profiles and the effect on daily functioning and quality of life, both outcomes with great impact on migraine patients. Disclosure: Dr. Straube has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Allergosan, Bayer, electroCore, Eli Lilly, Novartis, TEVA. Dr. Straube has received research support from Novartis Pharma. Dr. Stude has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arztekammer, Amgen, Hormosan, Lilly, Novartis, Teva. Dr. Gaul has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan Pharma, Ratiopharm, Boehringer Ingelheim Pharma, Lilly, Novartis Pharma, Desitin Arzneimittel, Cerbotec, Bayer vital, Hormosan Pharma, electroCore, Reckitt Benckiser, and Teva. Dr. Koch has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma. Dr. Schuh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma GmbH, Germany.